Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

CT pulmonary angiography and pulmonary embolism

Essential points for quick revision.

Saved on this device
!
Shock with suspected PE needs parallel action

Hypotension, syncope, severe hypoxaemia, right-heart failure or cardiac arrest may represent high-risk pulmonary embolism, and transfer for imaging can be unsafe.

Action: Begin resuscitation, call senior emergency, critical-care and specialist help, assess whether immediate bedside cardiac or venous imaging will change treatment, and obtain CTPA only when the patient can undergo it safely without delaying life-saving therapy.

Synopsis

Select and interpret CTPA within a probability-based pulmonary embolism pathway, recognise technical and clinical limits and act safely on positive, negative or indeterminate results.

  • Use the two-level PE Wells score before imaging: a score above 4 is PE likely and leads to immediate CTPA in an eligible stable adult.
  • If CTPA cannot be performed immediately in a likely PE and bleeding risk permits, give interim therapeutic anticoagulation while definitive testing is arranged.
  • After an adequate negative CTPA or V/Q study, consider proximal leg ultrasound if DVT is suspected; otherwise stop interim therapeutic anticoagulation without stopping separately indicated anticoagulation, pursue alternatives and give recurrence safety-net advice. Treat a technically inadequate study as indeterminate.

Key red flags

Haemodynamic instability, obstructive shock, cardiac arrest or rapidly worsening oxygenation with suspected PE requires a high-risk pathway rather than routine outpatient imaging.

A technically inadequate CTPA cannot exclude embolism; poor contrast timing, motion, low cardiac output and streak artefact must be stated and the diagnostic pathway continued.

An adequate negative CTPA or V/Q study enters the NICE negative-imaging branch; a technically inadequate study must be labelled indeterminate and cannot be used to exclude PE.

Contrast allergy, pregnancy and severe renal impairment alter modality choice and preparation; they do not justify abandoning investigation of a consequential PE.

Right-heart strain on CT can identify adverse risk but is not specific to acute PE and should be integrated with physiology, biomarkers and echocardiography.

Right-heart strain

Right ventricular enlargement, septal flattening and contrast reflux support pressure overload but can be chronic or caused by other pulmonary vascular disease.

Technical failure

Poor arterial enhancement, respiratory motion or streak artefact can make a scan indeterminate; the report must name the limitation and next action.

Investigation priorities

01
CT pulmonary angiographyFirst step

Confirm or exclude pulmonary arterial emboli and identify right-heart effects or an alternative thoracic diagnosis.

Management branches

Worked case: PE likelyStable adult proceeds to CTPA

A haemodynamically stable adult has suspected PE and a two-level Wells score above 4.

  1. Check physiological stability, bleeding risk, renal function when available, prior contrast reaction, pregnancy possibility and whether CTPA can be performed immediately.
  2. Offer immediate CTPA; if it is delayed, give interim therapeutic anticoagulation when appropriate rather than leaving a likely PE untreated.
Contrast-limited routeUse VQ imaging when suitable

A stable patient needs definitive PE imaging but has severe iodinated-contrast allergy or severe renal impairment.

Open full textbook Answer 2 questions
Sources and review status4 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom